Page last updated: 2024-11-07

dichlororibofuranosylbenzimidazole and Cancer of Prostate

dichlororibofuranosylbenzimidazole has been researched along with Cancer of Prostate in 2 studies

Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.

Research Excerpts

ExcerptRelevanceReference
"Effective treatments for advanced prostate cancer are much needed."1.35Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors. ( Cheng, JQ; Chu, B; Djeu, J; Mohapatra, S; Pledger, WJ; Zhao, X, 2009)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mohapatra, S1
Chu, B1
Zhao, X1
Djeu, J1
Cheng, JQ1
Pledger, WJ1
Lee, DK1
Duan, HO1
Chang, C1

Other Studies

2 other studies available for dichlororibofuranosylbenzimidazole and Cancer of Prostate

ArticleYear
Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors.
    The international journal of biochemistry & cell biology, 2009, Volume: 41, Issue:3

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Caspase 9; Cell Line, Tumor; Chlorp

2009
Androgen receptor interacts with the positive elongation factor P-TEFb and enhances the efficiency of transcriptional elongation.
    The Journal of biological chemistry, 2001, Mar-30, Volume: 276, Issue:13

    Topics: Cell Line; Cell Nucleus; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinases; Dichlororibofuranosylb

2001